SCHEMBL12896000

SCHEMBL12896000

C=CCc1ccc(Br)cc1C(C)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.45
MAOA P21397 3/20 0.42
CES2 O00748 1/20 0.38
GALR3 O60755 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
CASP1 P29466 1/20 0.38
CYP2C19 P33261 1/20 0.38
MAPT P10636 4/20 0.37
LMNA P02545 3/20 0.37
KMT2A Q03164 2/20 0.37
GAA P10253 1/20 0.37
ALOX12 P18054 1/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPK1 P28482 2/20 0.36
MAOB P27338 2/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31519069 0.85 KDM4E (0.49) PTGDR2CES2GALR3CYP1A2CYP2C9
SCHEMBL7867138 0.83 NR4A2 (0.44) CYP1A2CYP2C9HPGDCYP2C19MAPT
SCHEMBL12093772 0.81 L3MBTL1 (0.42) HPGDMAPTLMNAKMT2AALDH1A1
SCHEMBL12302945 0.80 PTGDR2 (0.51) PTGDR2MAOACES2GALR3CYP1A2
SCHEMBL12896001 0.79 PTGDR2 (0.50) PTGDR2MAOACES2GALR3CYP1A2
SCHEMBL436493 0.78 ALOX5 (0.45) MAPTLMNAKMT2AGAAALOX12
SCHEMBL5576681 0.76 KDM4E (0.46) PTGDR2MAPTLMNAKMT2AGAA
SCHEMBL31519072 0.76 KDM4E (0.46) PTGDR2MAPTLMNAKMT2AGAA
SCHEMBL22341038 0.75 KMT2A (0.38) HPGDMAPTLMNAKMT2AGAA
SCHEMBL3251271 0.75 CYP3A4 (0.47) CYP1A2HPGDCYP2C19MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321731-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-04-26 US disclosed
US-20160031820-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-04 US disclosed
US-9096518-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-08-04 US disclosed
US-20110039827-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039827-A1 Substituted hydroxamic acids and uses thereof HDAC6, HDAC5, HDAC1 PTGDR2 2707/4885MAOA 519/4885CES2 2572/4885
US-20160031820-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC5, HDAC1 PTGDR2 2707/4885MAOA 519/4885CES2 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.